Parallel Sessions


The life cycle of antiepileptic drugs

Wednesday 14 September 14:30 - 16:00

Co-chairs: Heinz Beck (Germany), Torbjörn Tomson (Sweden)

Pitfalls of preclinical studies: a tale of networks and power – Heinz Beck (Germany)

Pitfalls of clinical studies - Jacqueline French (USA)

Pitfalls during and after approval of antiepileptic drugs – Hajo Hamer (Germany)


Purkinje's Symposium - The cerebellum and epilepsy

Monday 12 September 14:30 - 16:00

Co-Chairs: Philippe Kahane (France), Kristina Malmgren (Sweden)

Cerebellar connections and interactions with the cerebral cortex – Richard Apps (United Kingdom)

Epilepsy and cerebellar atrophy – Milan Brázdil (Czech Republic)

Cerebellar epilepsy – is it a myth? – Hans Holthausen (Germany)

Cerebellar neurostimulation in the treatment of epilepsy – Gregory Krauss (USA)


Challenges of drug development for neonatal seizures

Sunday 11 September 14:30 - 16:00

Co-Chairs: Michele Simonato (Italy), Cecilie Johannessen Landmark (Norway)

Finding the right animal model – Stéphane Auvin (France)

Translational aspects - developing innovative drugs - Aristea Galanopoulou (USA)

Pitfalls of AED trials in neonatal seizures – Ronit Pressler (United Kingdom)

Developing innovative methods – Catherine Chiron (France)


Seizure detection in the EMU (Epilepsy Monitoring Unit)

Sunday 11 September 14:30 - 16:00

Co-Chairs: Sándor Beniczky (Denmark), Rainer Surges (Germany)

Automatic seizure detection system for epilepsy monitoring units - Christoph Baumgartner (Austria)

The detection of active epilepsy in the scalp EEG – Francesca Pittau (Switzerland)

Seizure prediction and treatment using intracranial EEG – Paul Boon (Belgium)

Multi-model seizure detection, which modality tells us most? – Sándor Beniczky (Denmark)


Marcus Marci's Symposium - What is a seizure? New perspectives

Tuesday 13 September 14:30 - 16:00

Co-Chairs: John Jefferys (United Kingdom), Wilson Truccolo (USA)

Are seizures really random events? – Premysl Jiruska (Czech Republic)

TBC - Wilson Truccolo (USA)

Neuronal behavior during seizure: insights from human patients - Catherine Schevon (USA)

Genetic therapy to control seizures in humans – sci-fi or reality? - Robert Wykes (United Kingdom)


ATP1A3 related epilepsies: novel phenomena, therapeutic insights and underlying pathophysiology

Tuesday 13 September 14:30 - 16:00

Co-Chairs: Alexis Arzimanoglou (France), Catherine Chiron (France)

Epilepsies in Alternating Hemiplegia of Childhood and other ATP1A3 related diseases – Eleni Panagiotakaki (France) & Hendrik Rosewich (Germany)

Acute and long term management of seizures and related disorders in alternating hemiplegia of childhood – Federico Vigevano (Italy)

Underlying pathophysiology of ATP1A3 related epilepsies: animal models and the promise of novel therapies – Mohamad Mikati (USA)


The current role of valproic acid in epilepsy therapy

Monday 12 September 14:30 - 16:00

Co-Chairs: Matthew Walker (UK), Svein I. Johannessen (Norway)

The story of valproate and how it changed the course of history of epilepsy treatment - Simon Shorvon (UK)

How valproic acid structure and clinical experience affected the design of its 2nd generation antiepileptic drugs - Meir Bialer (Israel)

Is valproic acid such a terrible teratogen? From the basic science point of view - Richard F. Finnell (USA)

Clinical teratogenicity and impact of EMA’s warning on the use of valproic acid in women – Torbjörn Tomson (Sweden)


Epilepsy and intellectual disability

Monday 12 September 14:30 - 16:00

Co-Chairs: Christian Brandt (Germany), Christoph Helmstaedter (Germany)

Epidemiology of epilepsy and intellectual disability in Europe – Christine Linehan (Ireland)

Efficacy of antiepileptic drug treatment in persons with epilepsy and intellectual disability – Mike Kerr (United Kingdom)

Assessment of drug side effects in persons with intellectual disability - Christian Brandt (Germany)

Epilepsy surgery in patients with epilepsy and intellectual disability – Vicente Villanueva (Spain)


Mechanisms of epileptogenicity in human brain lesions

Monday 12 September 14:30 - 16:00

Co-Chairs: Albert Becker (Germany), Dimitri Kullmann (UK)

Mechanisms underlying seizure generation around human glioma – Gilles Huberfeld (France)

LIM-domain-binding proteins: role for epilepsy development in glioneuronal tumours - Albert Becker (Germany)

Selective  silencing of parvalbumin interneurons in the subiculum induces recurrent spontaneous seizures - Günther Sperk (Austria)

Impaired intrinsic plasticity in hippocampal epileptogenesis – Yoel Yaari (Israel)


Novel therapies for status epilepticus (SE)

Tuesday 13 September 14:30 - 16:00

Co-Chairs: Reetta Kälviäinen (Finland), EugenTrinka (Austria)

New approaches to treatment of acute seizures and the early stage of status epilepticus - Simon Shorvon (UK)

The potential of valproic acid derivatives valnoctamide and SPD in treatment of benzodiazepine-resistant status epilepticus (stage of established status epilepticus) - Meir Bialer (Israel)

Allopregnanolone (SAGE 547) potential in the treatment of refractory and super refractory status epilepticus - Michael Rogawski (USA)

Challenges for novel therapies in the acute epilepsy setting – Industry perspective – Andreja Avbersek (Belgium)


MicroRNA as meta-controllers of gene expression in epilepsy: targets, diagnostics and opportunities for treatment

Sunday 11 September 14:30 - 16:00

Co-Chairs: Eleonora Aronica (The Netherlands), David Henshall (Ireland)

microRNA and inflammation: new therapeutic opportunities in epilepsy associated pathologies – Annamaria Vezzani (Italy)

microRNA as mechanism-linked biomarkers of epileptogenesis – David Henshall (Ireland)

Methodical approaches to PCR based quantification of miRNA in epilepsy – Petra Bencúrová (Czech Republic)

microRNAs control neuronal morphology in health and disease – Vamshidhar R. Vangoor (Netherlands)


Alterations of consciousness in epilepsy: a developmental trajectory?

Tuesday 13 September 14:30 - 16:00

Co-Chairs: Andrea Cavanna (United Kingdom), Adam Zeman (United Kingdom)

Common mechanism of loss of consciousness in seizures – Hal Blumenfeld (USA)

Ictal consciousness in children with temporal lobe epilepsy: clinical, neurophysiological and neuroimaging correlates – Stefano Seri (United Kingdom)

Intracranial recording and ictal consciousness in temporal lobe epilepsy – Fabrice Bartolomei (France)

Clinical assessment of ictal consciousness in epilepsy across the lifespan - Andrea Cavanna (United Kingdom)


The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools

Wednesday 14 September 16:30 - 18:00

Co-Chairs: Ingmar Blümcke (Germany), Betül Baykan (Turkey)

Epigenetic biomarkers in FCD – Katja Kobow (Germany)

New diagnostic tools in FCD (clinical) – Roberto Spreafico (Italy)

New challenges in FCD: molecular mechanisms of epileptogenesis – Eleonora Aronica (The Netherlands)


The burden and care of epilepsy in Europe

Sunday 11 September 14:30 - 16:00

Co-Chairs: Jakob Christensen (Denmark), Ettore Beghi (Italy)

The prevalence of epilepsy: does it vary across Europe? - Christine Linehan (Ireland)

Assessing the cost of epilepsy: methodological aspects - Poul Jennum (Denmark)

Epilepsy, stigma and quality of life: what is the situation in Europe? - Ettore Beghi (Italy)

ESBACE: an EU-funded study of the burden and care of epilepsy in Europe - Jakob Christensen (Denmark)


The mysteries of insular epilepsy

Tuesday 13 September 14:30 - 16:00

Co-Chairs: Milan Brázdil (Czech Republic), Mark Richardson (United Kingdom)

Anatomo-functional organisation of the insular cortex: the many faces of a small island - François Mauguière (France)

Electroclinical manifestations of insular seizures: the great mimicker - Philippe Kahane (France)

Insular seizures and SUDEP - Rainer Surges (Germany)

Surgery of insular epilepsy: yes you can! - Pavel Kršek (Czech Republic)


Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more?

Wednesday 14 September 16:30 - 18:00

Co-Chairs: Edouard Hirsch (France), Helen Cross (United Kingdom)

Rolandic epilepsy to epilepsy with CSWS via Landau-Kleffner syndrome: one syndrome or many? – Eliane Roulet-Perez (France)

Insights into neuropsychological impairments from functional neuroimaging - Patrick Van Bogaert (Belgium)

Can molecular genetics reveal mechanisms and novel targets for therapy? - Pierre Szepetowski (France)

The evidence base for pharmacological therapy and treatment paradigms - Floor Jansen (The Netherlands)


Mendel's Symposium - Molecular genetic testing in epilepsies anno 2016: an essential diagnostic tool

Wednesday 14 September 16:30 - 18:00

Co-Chairs: Peter De Jonghe (Belgium), Vladimir Komarek (Czech Republic)

Molecular diagnosis in genetic epilepsies: complexity, needs, tools and opportunities - Sarah Weckhuysen (France)

Next generation sequencing with gene panels: a revolution in molecular diagnostics - Johannes Lemke (Germany)

Whole exome sequencing (WES) in diagnostics; the new kid on the block - Heather Mefford (USA)

Copy number variants: now easy to detect but still difficult to interpret - Ingo Heilbig (Germany)


Seizures and stroke: from bad to worse and what could be done about it?

Wednesday 14 September 14:30 - 16:00

Chair: Ivan Rektor (Czech Republic)

A devastating outcome of a devastating disease: implications for patients and burden for society - Alla Guekht (Russia)

Seizures after stroke - can we predict? - Miri Neufeld (Israel)

Stroke after seizures - Eugen Trinka (Austria)

Seizures after stroke - can we prevent? - Felix Rosenow (Germany)


Inhibition synchronization ahead of seizures – protective or harmful?

Wednesday 14 September 14:30 - 16:00

Co-Chairs: Marco de Curtis (Italy), Roberto Spreafico (Italy)

Ictal onset and inhibitory networks: inhibition precipitates seizures - Massimo Avoli (Canada / Italy)

The concept of seizure penumbra: inhibition protects against seizures - Andrew Trevelyan (UK)

Optogenetic challenge of inhibitory networks and ictogenesis - Merab Kokaia (Sweden)

GABAergic neurons in human epileptic networks - Roberto Spreafico (Italy)


Neuroinflammation: a treatment target for early life epileptic encephalopathies?

Sunday 11 September 16:30 - 18:00

Co-Chairs: Aristea Galanopoulou (USA), Annamaria Vezzani (Italy)

Perinatal inflammation: does it contribute to neurodevelopmental deficits? - Stefanie Dedeurwaerdere (Belgium)

Early life inflammation: putative role in the pathogenesis of early life epileptic encephalopathies - Aristea Galanopoulou (USA)

In vivo biomarkers of neuroinflammation: can they track disease progression? - Teresa Ravizza (Italy)

From bench and bedside: can we envision novel pathway specific strategies for targeting neuroinflammation in early life epileptic encephalopathies? - Stéphane Auvin (France)


Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery

Wednesday 14 September 16:30 - 18:00

Co-Chairs: Ylva Østby (Norway), Miri Neufeld (Israel)

In search of memory networks in TLE –new evidence and opportunities using fMRI - Mary Pat McAndrews (Canada)

Localization/lateralization diagnostics and their value for monitoring of the course and the surgical treatment of TLE - Christoph Helmstaedter (Germany)

Memory and the brain in temporal lobe epilepsy –integrating basic science and clinical perspectives in epilepsy surgery - Ylva Østby (Norway)